rs72558478
Variant summary
Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM1PM2PP2PP3_StrongPP5_Very_Strong
The NM_000531.6(OTC):c.988A>G(p.Arg330Gly) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. R330R) has been classified as Likely benign.
Frequency
Consequence
NM_000531.6 missense
Scores
Clinical Significance
Conservation
Publications
- ornithine carbamoyltransferase deficiencyInheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P, Laboratory for Molecular Medicine, Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 17 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| OTC | NM_000531.6 | c.988A>G | p.Arg330Gly | missense_variant | Exon 9 of 10 | ENST00000039007.5 | NP_000522.3 | |
| OTC | NM_001407092.1 | c.988A>G | p.Arg330Gly | missense_variant | Exon 11 of 12 | NP_001394021.1 | ||
| OTC | XM_017029556.2 | c.*121A>G | downstream_gene_variant | XP_016885045.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
not provided Pathogenic:2
The R330G variant has been published previously as a pathogenic variant in patients with ornithine transcarbamylase (OTC) deficiency (Tuchman et al. 1997; McCullough et al. 2000; Nagasaka et al. 2013). The R330G variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R330G variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Furthermore, missense variants in nearby residues (E326K, W332R, M335I) have been reported in the Human Gene Mutation Database in association with OTC deficiency (Stenson et al., 2014), supporting the functional importance of this region of the protein. Therefore, we interpret the R330C variant to be likely pathogenic; however, the possibility that it is benign cannot be excluded. -
- -
Ornithine carbamoyltransferase deficiency Pathogenic:1
This sequence change replaces arginine with glycine at codon 330 of the OTC protein (p.Arg330Gly). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and glycine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with ornithine transcarbamylase deficiency (PMID: 9266388, 10946359, Invitae). ClinVar contains an entry for this variant (Variation ID: 97376). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt OTC protein function. For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at